Shanghai Juncell Therapeutics

Quick facts

Phase 2 pipeline

• GC101 TIL

Phase 1 pipeline

• Engineering Tumor Infiltrating Lymphocytes
• GC101TIL
• GC203 TIL
• Membrane Bound Cytokine Modified TIL
• Signal Switch Receptor Modified TIL
• TIL therapy
• Tumor Infiltrating Lymphocyte

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Shanghai Juncell Therapeutics portfolio CI brief
• Shanghai Juncell Therapeutics pipeline updates RSS